Abiogen Pharma out-licenses rights to market Attila in China and nearby territories to Lee's Pharma

Italian drugmaker Abiogen Pharma has signed a license, distribution and supply agreement with Hong Kong-based Lee's Pharmaceutical (HKEx: 0950) for Attila (neridronic acid) throughout China, Hong Kong, Macau and Taiwan.

Under the term of the accord, Abiogen granted Lee's Pharma an exclusive license and right for registering, importing, marketing, distributing and selling Attila in the territory, for the two orphan/rare disease indications - Osteogenesis Imperfecta (OI) and complex regional pain Syndrome (CRPS).

Neridronate is the only therapeutic agent approved in the world for such orphan diseases: OI (1 in 10,000 in UE) and CRPS (3 in 10,000 in UE). Attila is registered in Italy and used by patients in 32 European countries under the trade name Nerixia. Neridronate showed superior safety profile in long-term use and is highly tolerated by adults and pediatric population. It is the only bisphosphonate indicated for use in neonates and children.